San Antonio Breast Cancer Symposium 2008: BIG 1-98: Letrozole vs tamoxifen

Statin use & cholesterol in estrogen receptor-positive breast cancer treated with endocrine therapyПодробнее

San Antonio Breast Cancer Symposium 2008: Zoledronic acid may have anti-tumour propertiesПодробнее

Dr. William Gradishar Discusses 10 Years of Adjuvant TamoxifenПодробнее

TAM-01: low-dose tamoxifen in women with breast intraepithelial neoplasiaПодробнее

How to cope with Tamoxifen and LetrozoleПодробнее

GS2-04: "Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor..."Подробнее

San Antonio Breast Cancer Symposium 2008: Hormone supplements reduce death from breast cancerПодробнее

Professor Mitch Dowsett - Tamoxifen vs Aromatase InhibitorsПодробнее

San Antonio Breast Cancer Symposium 2022 highlightsПодробнее

Highlights from the San Antonio Breast Cancer Symposium 2022Подробнее

How Do Tamoxifen and Femara Fight Breast Cancer? | HealthПодробнее

San Antonio Breast Cancer Symposium 2008: Use of written forms doubles breast cancer detection rateПодробнее

Dr. Bora Lim | Challenging Types of Breast Cancer | SABCS 2022 | Education SessionПодробнее

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifenПодробнее

BIG 1-98 TrialПодробнее

Update from the 35th Annual San Antonio Breast Cancer Symposium.Подробнее

GS2-05: "Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian..."Подробнее

Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast CancerПодробнее

The San Antonio Breast Cancer Symposium (SABCS) 2022Подробнее